Day: June 20, 2025

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADAResults from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo1 Safety and tolerability of the higher dose of Wegovy® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg)1 The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesityBagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions.1,2 Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet.3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. “The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “The preclinical data being presented at ADA include the robust weight-loss...

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 19, 2025. A total of 864,407,409 common shares were voted at the Meeting, representing 65.42% of the votes attached to all outstanding common shares. Shareholders voted overwhelmingly in favour of all items of business before the Meeting. The ten director nominees listed in B2Gold’s Management Information Circular (the “Circular”) dated May 2, 2025, were elected as directors of B2Gold to hold office for the ensuing year or until their successors are elected or appointed. Detailed results of the vote for each director are set out below:Name Total...

LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025 Vancouver, June 20, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces results for the fiscal period ending April 30, 2025. All references to dollar amounts in this release are in Canadian dollars. Highlights During and After the Quarter During the three months ended April 30, 2025: •        On February 9, 2025, the Company provided an update on a Rapid Development Plan (“RDP”) for Norra Kärr, to be in production in the shortest possible timeframe, supplying HREE-rich eudialyte concentrate and industrial mineral nepheline syenite. •        The Company provided an update on the value creation options being considered for Woxna Graphite, on February 16, 2025, including...

Phoenix, AZ, June 20, 2025 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) reported Hotel Revenue results surpassing $2 million once again in the First Fiscal Quarter of 2026, (February 1, 2025, to April 30, 2025), with Total Revenue of approximately $2.2 million. Consolidated Net Income before non-cash depreciation expense was $221,330 for the 2026 First Fiscal Quarter ended April 30, 2025 (February 1, 2025, through April 30, 2025). Total Consolidated Fiscal First Quarter Net Income remained positive, at $39,030. IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025, and are contributing to a solid start in the current 2026 Fiscal Year. Combined Hotel May Revenue for both hotels was a notable $632,584, which has led to another remarkable Hotel Revenue amount of $2,838,347 for the first...

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted 799,920 restricted share units (“RSUs”) and 162,480 stock options (“Options”) to officers, directors, consultants and employees of the Company. The Options are each exercisable for one common share of the Company at an exercise price of C$0.50 per share for a period of three years from the grant date and vest over a one-year term. 700,000 RSUs are valid for a term of five years and 99,920 RSUs are valid for a term of three years. All RSUs vest over a period of one year from the grant date. All Options and RSUs are subject to the terms of the Company’s equity plans and applicable securities law hold periods. Further, the Company announces that it has engaged FN Media...

New York, New York, June 20, 2025 (GLOBE NEWSWIRE) — Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the “Company”) today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company’s units commenced trading on the Nasdaq Global Market (“Nasdaq”) under the symbol “AXINU” on June 18, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of one Class A ordinary share upon the consummation of the Company’s initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares...

BROOKLYN, N.Y., June 20, 2025 (GLOBE NEWSWIRE) — Pioneer Acquisition I Corp (Nasdaq: PACHU) (the “Company”) today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including the issuance of 3,300,000 units as result of the underwriters’ exercise of its over-allotment option in full. The gross proceeds from the offering were $253 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “PACHU” on June 18, 2025. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading,...